Dianthus TherapeuticsDNTH +2.00%22 Cash Ratio is 29.03 as of Mar. 2026, which is 87% above its 10-year median of 15.53. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $2.92 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,385 Biotechnology companies, Dianthus Therapeutics ranks better than 96.46% on this metric.
Dianthus Therapeutics has a Cash Ratio of 29.03. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Dianthus Therapeutics's Cash Ratio or its related term are showing as below:
DNTH'
s Cash Ratio Range Over the Past 10 Years
Min: 1.43 Med: 15.53 Max: 42.08
Current: 29.03
During the past 5 years, Dianthus Therapeutics's highest Cash Ratio was 42.08. The lowest was 1.43. And the median was 15.53.
DNTH's Cash Ratio is ranked better than 96.46% of 1385
companies
in the Biotechnology industry
Industry Median: 2.95
vs DNTH: 29.03
Dianthus Therapeutics (NAS:DNTH) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Dianthus Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dianthus Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Dianthus Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dianthus Therapeutics (DNTH) has a Cash Ratio of 29.03 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Dianthus Therapeutics and its competitors. This is 87% above median its historical median of 15.53. Over the past decade, Dianthus Therapeutics' Cash Ratio has ranged from 1.43 to 42.08. According to the industry distribution chart, Dianthus Therapeutics ranks #49 out of 1385 companies in the Biotechnology industry, placing it in the top 3.5%.
Is Dianthus Therapeutics' Cash Ratio too high?
Dianthus Therapeutics' current Cash Ratio of 29.03 is 87% above median its 10-year median of 15.53. Over the past 10 years, this metric has ranged from a low of 1.43 to a high of 42.08. The Biotechnology industry median Cash Ratio is 2.95. Dianthus Therapeutics' value of 29.03 is 884.1% above this industry median. Based on the distribution chart, Dianthus Therapeutics ranks #49 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Cash Ratio compare to CAI and TNGX?
According to the Biotechnology industry distribution chart, Dianthus Therapeutics ranks #49 out of 1385 companies for Cash Ratio. This places Dianthus Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.95. Dianthus Therapeutics' value of 29.03 is 884.1% above this benchmark. Historically, Dianthus Therapeutics' own Cash Ratio has ranged from 1.43 to 42.08 over the past decade. While the company's 10-year median is 15.53 vs. the industry median of 2.95, Dianthus Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dianthus Therapeutics's current Cash Ratio of 29.03 is 884.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Dianthus Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dianthus Therapeutics's current Cash Ratio is 29.03, which is 87% above median its own 10-year median of 15.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.92, compared to a current price of $100.03 — trading 3325.7% above its estimated fair value. The current Cash Ratio is 29.03, which is 87% above median its 10-year median of 15.53 and 884.1% above the Biotechnology industry median of 2.95. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Cash Ratio is 29.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dianthus Therapeutics (DNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued.
The current stock price of $100.03 is trading 3325.7% above its estimated GF Value™ of $2.92.
GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.
Key valuation signals for DNTH:
Cash Ratio: 29.03 (87% above median its 10-year median of 15.53)
GF Value™: $2.92 vs. price of $100.03 (3325.7% above fair value)
Industry Position: 884.1% above the Biotechnology median (#49 of 1385)
No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score
Get the complete analysis for DNTH
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNTH has been successfully added to your 
